Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

BMO Capital cut Terns Pharmaceuticals' price target from $26 to $15, citing costlier capital conditions despite maintaining ...

Pfizer's management has embarked on a comprehensive transformation strategy to address the challenges posed by the post-pandemic market and to position the company for sustainable growth. Key elements ...

In a recent ruling at London's High Court, Pfizer and its German partner BioNTech successfully invalidated two patents held by CureVac. This legal victory is a significant development in the ongoing ...

positioning it well for future growth despite recent market challenges. The legal battle began in 2020 when Pfizer accused SK bioscience of infringing on the composition patent of its own vaccine ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

David Risinger has given his Hold rating due to a combination of factors surrounding Pfizer’s current financial ... stems from projected revenue growth challenges over the next five years ...